BioSpero, Inc.
- Biotech or pharma, therapeutic R&D
- Medical device or technology
- Other products or services
- CMO, CRO
BioSpero is a pioneering biotechnology company specializing in Organ-on-Chip and microphysiological systems (MPS) for human-relevant preclinical testing. Our flagship platform, OrganXpert, emulates complex human organ functions—including liver, kidney, CNS, and cancer models—on advanced microfluidic chips, enabling highly predictive assessments of toxicity and efficacy.
OrganXpert features automated media recirculation, monitoring, and integrated incubation control to provide stable, scalable, and reproducible in vitro testing environments. The platform is designed to overcome the limitations of traditional animal models by improving translational accuracy and enabling ethical, efficient drug development.
Validated through collaborations with research hospitals, institutes, and universities, and supported by government-funded programs, BioSpero is now actively seeking strategic partners for platform adoption, co-development of clinical prediction models, and global market expansion.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}